Immunoglobulin E (IgE) bound to Artemisia vulgaris allergens (IgE-Art v complex)

Immunoglobulin E (IgE) bound to Artemisia vulgaris allergens is the primary molecular complex responsible for Type I hypersensitivity reactions in individuals sensitized to Mugwort pollen, a major cause of seasonal allergic rhinitis in Europe and Asia (Gadermaier et al., 2014). The complex forms when specific IgE antibodies, which are anchored to high-affinity receptors (FcεRI) on mast cells and basophils, recognize and bind to allergens such as Art v 1 (a defensin-like protein) or Art v 6 (a pectate lyase) (Himly et al., 2003). This binding event triggers the cross-linking of FcεRI receptors, leading to the rapid degranulation of these effector cells and the release of pro-inflammatory mediators like histamine and leukotrienes (Wopfner et al., 2005). These mediators drive the clinical symptoms of hay fever, including sneezing, rhinorrhea, and in some cases, allergic asthma. Therapeutic strategies targeting this interaction include the use of anti-IgE monoclonal antibodies like Omalizumab, which sequester free IgE to prevent its binding to receptors, and allergen-specific immunotherapy (AIT), which uses Mugwort pollen extracts to induce long-term immune tolerance (Bousquet et al., 2008). Monitoring levels of specific IgE against Art v 1 is a critical biomarker for diagnosing Mugwort allergy and assessing the potential efficacy of immunotherapy (Gadermaier et al., 2014).

Other names

Mugwort allergen-IgE complexArtemisia vulgaris pollen allergen-IgE complexIgE-Art v 1 complexIgE-Mugwort allergen complexIgE-Art v 6 complex

Anti-IgE monoclonal antibodies, such as Omalizumab, bind to the Cε3 domain of circulating Immunoglobulin E (IgE), preventing its interaction with the high-affinity IgE receptor (FcεRI) on the surface of mast cells and basophils (Noga et al., 2003). This sequestration reduces the amount of free IgE available to bind to Artemisia vulgaris allergens, thereby preventing the cross-linking of receptors and subsequent degranulation. Allergen-specific immunotherapy (AIT) involves the controlled administration of Artemisia vulgaris allergen extracts to induce immunological tolerance, characterized by the induction of regulatory T cells (Tregs) and a shift from a Th2-mediated allergic response to a Th1-mediated or tolerant response (Bousquet et al., 2008).